OncoMatch/Clinical Trials/NCT04799002
Topotecan and Melphalan for Retinoblastoma
Is NCT04799002 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Topotecan and Melphalan for retinoblastoma.
Treatment: Topotecan · Melphalan — The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Check if I qualifyEligibility summary
For patients with retinoblastoma.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify